Compare TransMedics Group Inc (TMDX) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Block Inc — how do they compare? TransMedics Group Inc trades at $87 (market cap $3.10B), while Block Inc trades at $78.45 (market cap $47.50B). The key difference: Block Inc is far larger — about 15.3× TransMedics Group Inc's market cap, and Block Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| TMDX | XYZ | |
|---|---|---|
Market Cap | $3.10B | $47.50B |
Sector | Technology | Technology |
52-Week High | $150.42 | $84.64 |
52-Week Low | $61.99 | $49.04 |
Enterprise Value | $3.49B | $42.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
XYZ trades at $77.97, down 1.28% on the day, with strong analyst support (75% buy ratings) and a $99.47 consensus price target. The stock shows bullish technical momentum with recent earnings beats in Q1 and Q2 2026, including Q2 EPS of $1.02 beating $0.871 estimates. Revenue reached $24.19B in 2025, though net margins remain thin at 1.43%. Recent news highlights Square's expanded credit card features and AI integration driving operational efficiency.
Outlook remains positive with raised 2026 guidance and 25% gross profit growth, though high P/E of 141.2 signals premium valuation. Key risks include competitive fintech pressure and execution on AI initiatives. Institutional buying and strong Cash App performance support upside potential toward price targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
